21 April 2025

ACR & Arthritis Foundation Denounce the Dismantling of Vital Health Programs

As organizations representing nearly 60 million adults and children living with arthritis in the United States and the rheumatologists and health care professionals who treat them, we are deeply alarmed by this week’s dismantling of multiple branches of the Centers for Disease Control and Prevention (CDC) that manage essential research and public health programs critical to the well-being of millions of people living with chronic conditions.

Retrospective EGPA study of mepolizumab Rx 45 pts Rx initially w/ 300 mg/4 weeks, 27% switched to 100 mg/4 wks a

Tweet Author

RheumNow

Tweet Content

Retrospective EGPA study of mepolizumab Rx 45 pts Rx initially w/ 300 mg/4 weeks, 27% switched to 100 mg/4 wks after 26 mos & 50% maintained complete remission without GC. Other half had sinonasal Sxs Rx w/ increased MEP dose orlocal therapy. https://t.co/M4Gp52QdwQ https://t.co/zb13fuKhpH

Links

Step-down treatment with mepolizumab for eosinophilic granulomatosis with polya… https://academic.oup.com/rheumatology/advance-article-abstract/doi/10.1093/rheu…

Genetic Sequencing in Rheumatology Genetic sequencing as a research and diagnostic tool has expanded in medicine and r

Tweet Author

RheumNow

Tweet Content

Genetic Sequencing in Rheumatology Genetic sequencing as a research and diagnostic tool has expanded in medicine and rheumatology. An interesting review in Arthritis and Rheumatology suggests that despite currently modest use, there will be an expanded role for genetic

The Increasing Cost of First-Line Biologics for Plaque Psoriasis A national commercial claims analysis of first-line u

Tweet Author

RheumNow

Tweet Content

The Increasing Cost of First-Line Biologics for Plaque Psoriasis A national commercial claims analysis of first-line use of biologics in biologic−naive plaque psoriasis patients found a near doubling of net treatment costs from 2007 to 2021 ($21 236 to $47 125). Despite the https://t.co/mWXz2o0mwz

Obesity is a risk factor for not achieving remission in early #RA (ERA), independent of comorbidity. 1285 ERA RA pts; re

Tweet Author

RheumNow

Tweet Content

Obesity is a risk factor for not achieving remission in early #RA (ERA), independent of comorbidity. 1285 ERA RA pts; remission failure @6 mos = 64% w/ obese, 52% if overWt & 48% if NL wt. RR 1.33 w/ no change after adjusting for RF/CCP, education, EtOH, smoking, phys activity, https://t.co/341ba1rCSk

21 April 2025

Diabetes Prevention with Hydroxychloroquine in Sjogren’s

A Taiwanese insurance claims analysis looked at hydroxychloroquine (HCQ) use in primary Sjögren syndrome (pSS) and showed that HCQ exposure significantly reduces the risk of new onset diabetes in pSS. Conversely, higher doses of glucocorticoids increased the risk of diabetes, but concurrent HCQ use mitigates this risk in a dose-dependent manner.

Everyone is entitled to his own opinion, but not his own facts. - Daniel Patrick Moynihan https://t.co/VQTvdtm9cw

Tweet Author

RheumNow

Tweet Content

Everyone is entitled to his own opinion, but not his own facts. - Daniel Patrick Moynihan https://t.co/VQTvdtm9cw

Distinguishing Septic and Gouty Arthritis A single center, retrospective review of patients undergoing knee joint flui

Tweet Author

RheumNow

Tweet Content

Distinguishing Septic and Gouty Arthritis A single center, retrospective review of patients undergoing knee joint fluid aspirations for presumed crystalline arthritis (CA) showed that synovial WBC may provide a useful diagnostic marker for SA with an optimal threshold of 50,000 https://t.co/ye69mRooSh

Predictors of Developing RA A prospective cohort study of seropositive arthralgia patients demonstrated that baseline

Tweet Author

RheumNow

Tweet Content

Predictors of Developing RA A prospective cohort study of seropositive arthralgia patients demonstrated that baseline characteristics and labs can be used to predict which arthralgia patients are at highest risk of developing RA. These studies underscore the influence of https://t.co/wpSHDfwCL7

Is High Dose Aspirin Needed in Kawasaki Disease (KD)? Does aspirin add any advantage to intravenous immunoglobulin (IV

Tweet Author

RheumNow

Tweet Content

Is High Dose Aspirin Needed in Kawasaki Disease (KD)? Does aspirin add any advantage to intravenous immunoglobulin (IVIG) alone in children with KD? A randomized clinical trial IVIG alone was not inferior to IVIG plus aspirin, suggesting that high-dose aspirin during initial https://t.co/uuCgDmgNif

Topics

ACR & Arthritis Foundation Denounce the Dismantling of Vital Health Programs

Retrospective EGPA study of mepolizumab Rx 45 pts Rx initially w/ 300 mg/4 weeks, 27% switched to 100 mg/4 wks a

Genetic Sequencing in Rheumatology Genetic sequencing as a research and diagnostic tool has expanded in medicine and r

The Increasing Cost of First-Line Biologics for Plaque Psoriasis A national commercial claims analysis of first-line u

Obesity is a risk factor for not achieving remission in early #RA (ERA), independent of comorbidity. 1285 ERA RA pts; re

Everyone is entitled to his own opinion, but not his own facts. - Daniel Patrick Moynihan https://t.co/VQTvdtm9cw

Distinguishing Septic and Gouty Arthritis A single center, retrospective review of patients undergoing knee joint flui

Predictors of Developing RA A prospective cohort study of seropositive arthralgia patients demonstrated that baseline

Is High Dose Aspirin Needed in Kawasaki Disease (KD)? Does aspirin add any advantage to intravenous immunoglobulin (IV

Do you get our email newsletter?